The m6A-related gene signature for predicting the prognosis of breast cancer

• Main Authors: Shanliang Zhong, Zhenzhong Lin, Huanwen Chen, Ling Mao, Jifeng Feng, Siying Zhou
• Format: Article
• Language: English
• Published: PeerJ Inc. 2021-06-01
• Series: PeerJ
• Subjects: Breast cancer; Breast neoplasms; m6A modification; IGF2BP1; Prognosis
• Online Access: https://peerj.com/articles/11561.pdf
• ISSN: 2167-8359

N6-methyladenosine (m6A) modification has been shown to participate in tumorigenesis and metastasis of human cancers. The present study aimed to investigate the roles of m6A RNA methylation regulators in breast cancer. We used LASSO regression to identify m6A-related gene signature predicting breast cancer survival with the datasets downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (TCGA). RNA-Seq data of 3409 breast cancer patients from GSE96058 and 1097 from TCGA were used in present study. A 10 m6A-related gene signature associated with prognosis was identified from 22 m6A RNA methylation regulators. The signature divided patients into low- and high-risk group. High-risk patients had a worse prognosis than the low-risk group. Further analyses indicated that IGF2BP1 may be a key m6A RNA methylation regulator in breast cancer. Survival analysis showed that IGF2BP1 is an independent prognostic factor of breast cancer, and higher expression level of IGF2BP1 is associated with shorter overall survival of breast cancer patients. In conclusion, we identified a 10 m6A-related gene signature associated with overall survival of breast cancer. IGF2BP1 may be a key m6A RNA methylation regulator in breast cancer.